(Reuters) - By Debra Sherman
CHICAGO, Aug 3 - Boston Scientific Corp.'s decision not to divest part of its Endosurgery business signaled the medical devices company has confidence it can pare down its sizable debt through other means and would be better off hanging on to its most stable product line, analysts said.
Read more at Reuters.com Mergers News
CHICAGO, Aug 3 - Boston Scientific Corp.'s decision not to divest part of its Endosurgery business signaled the medical devices company has confidence it can pare down its sizable debt through other means and would be better off hanging on to its most stable product line, analysts said.
Read more at Reuters.com Mergers News
No comments:
Post a Comment